[DOI] [PMC free article] [PubMed] [Google Scholar] 167.Shrivastava S, Bhanja Chowdhury J, Steele R, Ray R, Ray RB
doi: 10.1371/journal.pone.0296733 85 ShuchengH.LiJ.LiuY.ChenX.JiangX
The Future of Oral Peptide Drugs Heinis's team is now working on oral peptides for gastrointestinal diseases , including: Crohns disease Ulcerative colitis Bacterial infections Their first major success involves generating enzyme-resistant peptides targeting the interleukin-23 receptor , a key factor in inflammatory bowel disease (IBD)
Results vary based on starting weight, dose, and lifestyle habits
Los complementos alimenticios no deben ser utilizados como sustitutos de una dieta variada y equilibrada y un estilo de vida saludable
Preclinical studies suggest retatrutide may modulate cancer-related metabolic pathways